Insider Trading February 19, 2026

Corpay Director Sells $1.23M in Stock Amid Strong YTD Share Performance

Director Jeffrey Steven Sloan disposed of 3,600 shares on Feb. 17, 2026; company posts solid Q4 results and extends Rugby Australia partnership

By Sofia Navarro CPAY
Corpay Director Sells $1.23M in Stock Amid Strong YTD Share Performance
CPAY

Jeffrey Steven Sloan, a director at Corpay, Inc. (NYSE: CPAY), sold 3,600 shares of common stock on February 17, 2026, for $343.6154 per share, generating proceeds of $1.23 million. Following the sale he retains direct ownership of 12,474 shares. Corpay shares are trading at $349.19 and are up 16.04% year-to-date on InvestingPro data. The company recently reported better-than-expected fourth-quarter 2025 results and provided 2026 guidance that prompted UBS to raise its price target while keeping a Neutral rating. Corpay also extended its foreign exchange payments partnership with Rugby Australia.

Key Points

  • Director Jeffrey Steven Sloan sold 3,600 shares on February 17, 2026, at $343.6154 per share, raising $1.23 million; he now directly owns 12,474 shares.
  • Corpay shares are trading at $349.19 and are up 16.04% year-to-date; the company has a market capitalization of $24.43 billion and a P/E ratio of 23.22.
  • The company beat Q4 2025 expectations with EPS of $6.04 (vs. $5.93 expected) and revenue of $1.25 billion (vs. $1.23 billion expected); UBS raised its price target from $315 to $380 while keeping a Neutral rating, and Corpay extended its foreign exchange payments partnership with Rugby Australia.

Corpay, Inc. (NYSE: CPAY) disclosed that director Jeffrey Steven Sloan sold 3,600 shares of the company’s common stock on February 17, 2026, at a transaction price of $343.6154 per share. The sale produced total proceeds of approximately $1.23 million. After the disposition, Sloan directly holds 12,474 shares of Corpay.

Shares of Corpay are trading at $349.19 and have delivered a year-to-date gain of 16.04%, according to InvestingPro data. The company carries a market capitalization of $24.43 billion and a price-to-earnings ratio of 23.22, trading near InvestingPro’s assessment of its Fair Value. Analysts covering the name maintain a consensus "Buy," with price targets spanning from $340 to $440. Corpay’s detailed Pro Research Report is listed among more than 1,400 coverage profiles on InvestingPro.


Recent financial performance

Corpay reported results for the fourth quarter of 2025 that exceeded analyst expectations. The company recorded earnings per share of $6.04, ahead of the $5.93 consensus estimate, while revenue reached $1.25 billion versus the $1.23 billion expected. In response to Corpay’s formal guidance for 2026, UBS raised its price target on the stock from $315 to $380 and retained a Neutral rating.

UBS’s updated target reflects the company’s guidance, which includes management’s projection of 10% organic revenue growth for 2026. That outlook is consistent with the preliminary guidance Corpay shared during its third-quarter earnings update.


Strategic partnerships

On the commercial front, Corpay extended a multi-year agreement with Rugby Australia, remaining the Official Foreign Exchange Payments Partner for both the men’s and women’s national rugby teams. The renewal underscores continued commercial engagement in sports-related payments activity.


What the filing shows

  • The director sale involved 3,600 shares at $343.6154 per share on Feb. 17, 2026, totaling $1.23 million.
  • Post-transaction direct holdings for Sloan stand at 12,474 shares.
  • Corpay’s stock trades at $349.19, up 16.04% year-to-date per InvestingPro.

These items provide a snapshot of recent insider activity alongside company fundamentals, quarterly performance and a renewed commercial partnership that together offer investors updated information on Corpay’s trajectory.

Risks

  • Analyst sentiment and price targets vary - while consensus is a Buy, UBS maintains a Neutral rating despite raising its price target, indicating mixed analyst views that could affect equity sentiment - impacts the financials and capital markets sectors.
  • Guidance dependence - UBS’s revision is tied to Corpay’s 2026 guidance which projects 10% organic revenue growth; if that guidance is not met, market expectations and valuation could be affected - impacts the payments and financial services sectors.

More from Insider Trading

Standex Director Disposes $513K in Stock as Company Posts Q2 Beat Feb 20, 2026 Sonoco Packaging Executive Disposes Small Stake as Company Outlines Multi-Year Earnings Goals Feb 20, 2026 Bank of the James President Buys $25,068 of Stock as Co-Founder Retires Feb 20, 2026 Bank of the James Director Adds $20,412 in Shares; Co-Founder Retires After Long Tenure Feb 20, 2026 Rogers Corp Director Disposes of 8,000 Shares; Stock Near Yearly High After Strong Quarter Feb 20, 2026